| 영문 | rheumatoid factor | 한글 | 류마티스 인자 |
|---|---|---|---|
| 설명 | IgG의 Fc부위에 있는 항원결정인자에 대한 항체로서 전형적인 또는 확실한 류마티스관절염(rheumatoid arthritis) 환자의 80%에서 발견된다. 류마티스 인자는 IgM, IgG, IgA중 하나가 될 수 있으나 주로 IgM이다. 소아류마티스관절염(juvenile rheumatoid arthritis: 소아기에 발생하는 류마티스관절염)을 비롯한, 다른 결합조직병이나 감염병에도 나타날 수 있다 |
||
| 영문 | growth factor | 한글 | 성장인자 |
|---|---|---|---|
| 설명 | 세포의 분화 및 성장에 관여하는 단백질. 성장인자는 정상 세포주기에 필수적이기 때문에 동물의 생명에 중대한 요소가 된다. 무엇보다도 성장인자는 태아의 발육을 조정하고 조직의 유지 및 보수에 중대한 역할을 하며, 혈구의 생성을 자극한다. 또한 암의 진행과정에도 관여한다. |
||
| 영문 | risk factor | 한글 | 위험인자 |
|---|---|---|---|
| 설명 | 국제방사선방호위원회(ICRP)가 1977년 권고에서 방사선방호의 목적으로 채택한 지수로, 단위선량(1 Sv)당 확률적 영향의 발생확률을 추정하여 나타낸 것이다. 생식선 선량에 대한 유전적영향의 발생률(4×10-3/Sv)이나 적색골수선량에 대한 백혈병 발생률(2×10-3/Sv)등 외에 뼈, 허파, 갑상샘, 젖샘, 기타 조직의 위험지수를 측정하여, 확률적 영향의 전신에 있어서 치사위험지수의 합계를 16.5×10-3/Sv로 하였다. 그후 ICRP는 1990년 권고에서 대상이 되는 조직과 장기를 추가하고, 수치 개정을 하면서 명칭도 각목적확률지수라고하였다. 이 권고에 의하면, 치사적 확률적 영향의 확률지수의 합계는, 일반인에 있어 60.0×10-3/Sv이다. |
||
| CF | calcaneal fibular [ligament]; calcium leucovorin; calf blood flow; calibration factor; cancer-free; ... |
|---|---|
| EF | ectopic focus; edema factor; ejection fraction; elastic fibril; electric field; elongation factor; e... |
| PF | pair feeding; peak flow; perfusion fluid; pericardial fluid; periosteal fibroblast; peritoneal fluid... |
| PAF | paroxysmal atrial fibrillation; peroxisomal assembly factor; phosphodiesterase-activating factor; pl... |
| SF | Sabin-Feldman [test]; safety factor; salt-free; scarlet fever; screen film; seminal fluid; serosal f... |
| AMF | Autocrine Motility Factor |
|---|---|
| AMF-R | Autocrine motility factor receptor |
| MMC | Migrating Motility Complex |
| SMI | Sperm Motility Index |
| %MOT | motility |
autodermic graft
IGF-II : insulin like growth factor-II의 약자. 많은 장기와 조직에 작용하여 단백 합성과 DNA, RNA의 합성을 증가시켜 세포의 수와 양을 증가
| autocrine motility factor | A member of the class of cytokines secreted by tumour cells. It elicits increases in cell motility and phosphoinositide metabolism in the secreting or producing cell via a pertussis toxin-sensitive g-protein signal transduction pathway. The factor has also been used as a marker for bladder cancer. (12 Dec 1998) |
|---|
| autocrine | <endocrinology> Secretion of a substance, such as a growth factor, that stimulates the secretory cell itself. One route to independence of growth control is by autocrine growth factor production. (02 Jan 1998) |
|---|---|
| autocrine communication | Denoting a type of cellular communication in which a hormone binds to receptors on and affects the function of the cell type that produced it. (12 Dec 1998) |
| autocrine hypothesis | That tumour cells containing viral oncogenes may have encoded a growth factor, normally produced by other cell types, and thereby produce the factor autonomously, leading to uncontrolled proliferation. (05 Mar 2000) |
| ciliary motility disorders | Disorders characterised by abnormal ciliary movement in the nose, paranasal sinuses, respiratory tract, and spermatozoa. Electron microscopy of the cilia shows that dynein arms are missing. The disorders manifest as kartagener triad (kartagener's syndrome), chronic respiratory disorders, chronic sinusitis, and/or chronic otitis. (12 Dec 1998) |
| motility | <biology> The ability to move spontaneously. (18 Nov 1997) |
| motility test | A test based on microscopic observation or on the spread of growth in soft agar, used to determine if a microorganism is motile. (05 Mar 2000) |
| motility test medium | A culture medium with a concentration of agar that produces a less solid consistency than usual and allows motile organisms to grow away from the line of inoculation; used to differentiate species of bacteria. (05 Mar 2000) |
| sperm motility | Ability of the spermatozoon to move by flagellate swimming. (12 Dec 1998) |
| ocular motility disorders | Disorders of eye movement resulting from malfunction of the sensory-motor mechanism of the eye which leads to faulty alignment of the eyes and/or visual impairment. (12 Dec 1998) |
| oesophageal motility disorders | Disorders affecting the motor function of the upper or lower oesophageal sphincters, the oesophageal body, or a combination of these parts. The failure of the sphincters to maintain a tonic pressure may result in the impeding of the passage of food, regurgitation of food, or reflux of gastric acid into the oesophagus. (12 Dec 1998) |
| accelerator factor | <chemical> Heat- and storage-labile plasma glycoprotein which accelerates the conversion of prothrombin to thrombin in blood coagulation. Factor v accomplishes this by forming a complex with factor xa, phospholipid, and calcium (prothrombinase complex). Deficiency of factor v leads to owren's disease. Chemical name: Blood-coagulation factor V (12 Dec 1998) |
| acetate replacement factor | <biochemistry> 1,2 dithiolane 3 valeric acid. Regarded as a coenzyme in the oxoglutarate dehydrogenase complex of the citric acid cycle. Involved generally in oxidative decarboxylations of _ keto acids. A growth factor for some organisms. (18 Nov 1997) |
| adrenal weight factor | A postulated substance of adenohypophysial origin responsible for maintenance of the weight of the adrenal cortex. (05 Mar 2000) |
| adrenocorticotropic releasing factor | Hormone produced by hypothalamus that causes pituitary to secrete adrenocorticotropic hormone. (05 Mar 2000) |
| a-factor | <molecular biology> A protein which is found in the bacterial genus Streptomyces that helps start the production of streptomycin and the process of morphological differentiation. It is used in biotechnology to induce these functions in mutant strains of Streptomyces that cannot produce it themselves. (09 Feb 1998) |
Synonyms : Tumor-Cell Autocrine Motility Factor, Motility Factor, Autocrine, Tumor Cell Autocrine Motility Factor
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|